Roivant Sciences and iNtRON Biotechnology have signed a $667.5m global licensing agreement for SAL200, which is an investigational biologic to treat infectious diseases caused by antibiotic-resistant staphylococci.

This licensing agreement consists of milestone payments along with royalties on net sales in the low double digits.

iNtRON Bio will receive milestone payments for development, regulatory, and sales-driven events.

On the other hand, Roivant has gained the option to license iNtRON Bio’s non-clinical stage, anti-Gram-positive endolysin programmes, which include anti-VRE and anti-TB biologics, for an additional amount of up to $45m each.

Roivant also got the first right of offer for anti-Gram-negative platform of iNtRON Bio.
Besides, it has set up a subsidiary to undertake global development and commercialisation of endolysin products from iNtRON Bio.

“This partnership with iNtRON represents our commitment at Roivant Pharma to deliver transformational therapeutics.”

The firm intends to begin a Phase II trial for SAL200 next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roivant Pharma president Mayukh Sukhatme said: “This partnership with iNtRON represents our commitment at Roivant Pharma to deliver transformational therapeutics.

“The development of novel anti-infective therapies is one of the greatest needs of our time and we hope to maximize the impact of SAL200 on public health through innovative approaches to both development and commercialisation.”

iNtRON Bio CEO Kyung Won Yoon said: “This partnership between iNtRON Bio and Roivant combines our industry-leading endolysin platform with their track record of operational excellence.

“Together we hope to ensure that physicians have better options in their armamentarium in preparation for the ‘post-antibiotic era’ on the horizon.”

With its base in South Korea, biotechnology company iNtRON Bio develops bacteriophage/endolysin-based antibacterials to treat serious infections.